Seaport Therapeutics to Present at Stifel 2026 Healthcare Conference

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement 

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement rap

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies

Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress

insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement

Seaport Therapeutics to Participate in September Investor Conferences

insitro Appoints Hideo Makimura as Chief Medical Officer to Lead Its Transition to a Clinical-Stage Company

Flare Therapeutics Appoints Peter Lebowitz, MD, PhD, to Board of Directors and Brian DeSchuytner as Chief Financial Officer and Chief Business Officer

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Maze Therapeutics to Participate in Three Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Septerna to Participate in Upcoming Investor Conferences

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

Maze Therapeutics Announces Appointments to Its Board of Directors

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Tango Therapeutics Announces Executive Chair Transition

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research

ARTBIO Appoints Jonathan Freeman Interim Chief Executive Officer

Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Trace Neuroscience Initiates Global Clinical Development Program for TRCN-1023, an Antisense Oligonucleotide Designed to Restore UNC13A Function for the Treatment of ALS

Experienced Neuropsychiatry Drug Development Leader Joins Syremis’ Executive Team Ahead of Key Pipeline Milestones

Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

insitro Presents New Data Demonstrating Its AI-Discovered MASH Candidate Shows Anti-Fibrotic Signal Beyond Liver-Fat Reduction at the American Diabetes Association 86th Scientific Sessions

Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Tango Therapeutics Announces Proposed $500 Million Public Offering

Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer

Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights